IL238536B - History of 6-oxo-6,1-dihydro-pyridazine for the treatment of hepatocellular carcinoma (hcc) - Google Patents

History of 6-oxo-6,1-dihydro-pyridazine for the treatment of hepatocellular carcinoma (hcc)

Info

Publication number
IL238536B
IL238536B IL238536A IL23853615A IL238536B IL 238536 B IL238536 B IL 238536B IL 238536 A IL238536 A IL 238536A IL 23853615 A IL23853615 A IL 23853615A IL 238536 B IL238536 B IL 238536B
Authority
IL
Israel
Prior art keywords
hcc
dihydro
oxo
treatment
hepatocellular carcinoma
Prior art date
Application number
IL238536A
Other languages
English (en)
Hebrew (he)
Other versions
IL238536A0 (en
Inventor
Friese-Hamim Manja
Friedhelm Bladt
Original Assignee
Merck Patent Gmbh
Manja Friese Hamim
Friedhelm Bladt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Manja Friese Hamim, Friedhelm Bladt filed Critical Merck Patent Gmbh
Publication of IL238536A0 publication Critical patent/IL238536A0/en
Publication of IL238536B publication Critical patent/IL238536B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
IL238536A 2012-11-02 2015-04-30 History of 6-oxo-6,1-dihydro-pyridazine for the treatment of hepatocellular carcinoma (hcc) IL238536B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12007494 2012-11-02
PCT/EP2013/002998 WO2014067610A1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)

Publications (2)

Publication Number Publication Date
IL238536A0 IL238536A0 (en) 2015-06-30
IL238536B true IL238536B (en) 2019-01-31

Family

ID=47143496

Family Applications (1)

Application Number Title Priority Date Filing Date
IL238536A IL238536B (en) 2012-11-02 2015-04-30 History of 6-oxo-6,1-dihydro-pyridazine for the treatment of hepatocellular carcinoma (hcc)

Country Status (26)

Country Link
US (1) US20150283137A1 (enExample)
EP (1) EP2914264B1 (enExample)
JP (1) JP6255028B2 (enExample)
KR (1) KR102131588B1 (enExample)
CN (1) CN104768553A (enExample)
AR (1) AR093318A1 (enExample)
AU (1) AU2013339823B2 (enExample)
BR (1) BR112015008279A2 (enExample)
CA (1) CA2890273C (enExample)
DK (1) DK2914264T3 (enExample)
ES (1) ES2646913T3 (enExample)
HK (1) HK1211869A1 (enExample)
HR (1) HRP20171295T1 (enExample)
HU (1) HUE035483T2 (enExample)
IL (1) IL238536B (enExample)
LT (1) LT2914264T (enExample)
MX (1) MX354518B (enExample)
NO (1) NO2914264T3 (enExample)
PL (1) PL2914264T3 (enExample)
PT (1) PT2914264T (enExample)
RS (1) RS56485B1 (enExample)
RU (1) RU2650679C2 (enExample)
SG (1) SG11201503214YA (enExample)
SI (1) SI2914264T1 (enExample)
WO (1) WO2014067610A1 (enExample)
ZA (1) ZA201503924B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2921310C (en) 2013-08-14 2021-04-20 Yugenkaisha Japan Tsusyo Hydroponic cultivation system, and plant factory comprising hydroponic cultivation system and expanded polystyrene foam greenhouse
LT3996688T (lt) * 2019-07-10 2023-12-27 Merck Patent Gmbh Farmacinis preparatas
JP2022551672A (ja) * 2019-10-14 2022-12-12 オラテック セラピューティクス リミティド ライアビリティ カンパニー 乳癌治療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
KR101829595B1 (ko) * 2009-01-08 2018-02-14 메르크 파텐트 게엠베하 3-(1-{3-[5-(1-메틸-피페리딘-4일메톡시)-피리미딘-2-일]-벤질}-6-옥소-1,6-디히드로-피리다진-3-일)-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법

Also Published As

Publication number Publication date
EP2914264A1 (en) 2015-09-09
MX2015005265A (es) 2015-07-17
HRP20171295T1 (hr) 2017-10-20
HK1211869A1 (en) 2016-06-03
CA2890273C (en) 2021-10-26
PT2914264T (pt) 2017-11-14
HUE035483T2 (hu) 2018-05-02
CA2890273A1 (en) 2014-05-08
SG11201503214YA (en) 2015-05-28
DK2914264T3 (en) 2017-09-11
AU2013339823A1 (en) 2015-06-18
IL238536A0 (en) 2015-06-30
US20150283137A1 (en) 2015-10-08
WO2014067610A1 (en) 2014-05-08
JP2015536957A (ja) 2015-12-24
KR102131588B1 (ko) 2020-07-08
BR112015008279A2 (pt) 2017-07-04
RU2650679C2 (ru) 2018-04-17
CN104768553A (zh) 2015-07-08
AU2013339823B2 (en) 2018-01-04
EP2914264B1 (en) 2017-08-09
PL2914264T3 (pl) 2017-12-29
KR20150079942A (ko) 2015-07-08
SI2914264T1 (sl) 2017-12-29
ES2646913T3 (es) 2017-12-18
MX354518B (es) 2018-03-08
AR093318A1 (es) 2015-05-27
NO2914264T3 (enExample) 2018-01-06
JP6255028B2 (ja) 2017-12-27
RS56485B1 (sr) 2018-01-31
RU2015120692A (ru) 2016-12-27
LT2914264T (lt) 2017-11-10
ZA201503924B (en) 2020-11-25

Similar Documents

Publication Publication Date Title
EP3685870B8 (en) Zone heating for respiratory circuits
IL237275A0 (en) Compounds for the treatment of paramoxovirus viral infections
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
LT2552438T (lt) Hepatoceliulinės karcinomos gydymo būdai
SG10201704992SA (en) Lsr antibodies, and uses thereof for treatment of cancer
SG11201503042QA (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
IL236037A0 (en) Pyridinone and pyridizinone derivatives
AP2015008968A0 (en) Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b
SG11201506099XA (en) Macrocyclic pyridazinone derivatives
GB201223466D0 (en) Time-based authentication
GB201219873D0 (en) Diverticulitis treatment
IL235693B (en) Biological therapy for the treatment of a malignant tumor of liver cells
IL237976A0 (en) A derivative of 7-azaindole-2,7-naphthyridine for the treatment of tumors
IL238536B (en) History of 6-oxo-6,1-dihydro-pyridazine for the treatment of hepatocellular carcinoma (hcc)
SG11201605501RA (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
IL236480B (en) A process for the preparation of n-oxides of 5-(1-alkylthio)alkyl-pyridine substituted in position 2
EP2826486A4 (en) PRODUCT FOR TREATING VIRAL HEPATITIS C
GB201319234D0 (en) Method for diagnosing hepatocellular carcinoma (HCC)
IL232340A0 (en) lsr antibodies, and their uses for cancer treatment
GB201215527D0 (en) Compounds for the treatment of muscular dystrophy

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed